Rational Design of Novel Therapies for Pantothenate Kinase–Associated Neurodegeneration

Molecular insights on the dynamic stability of peptide nucleic acid functionalized carbon and boron nitride nanotubes

Physical Chemistry Chemical Physics ◽

10.1039/d0cp05759b ◽

2021 ◽

Vol 23 (1) ◽

pp. 219-228

Author(s):

Nabanita Saikia ◽

Mohamed Taha ◽

Ravindra Pandey

Keyword(s):

Nucleic Acid ◽

Boron Nitride ◽

Nucleic Acids ◽

Dynamic Stability ◽

Peptide Nucleic Acid ◽

Rational Design ◽

Peptide Nucleic Acids ◽

Boron Nitride Nanotubes ◽

Molecular Hybrids ◽

Single Wall Nanotubes

The rational design of self-assembled nanobio-molecular hybrids of peptide nucleic acids with single-wall nanotubes rely on understanding how biomolecules recognize and mediate intermolecular interactions with the nanomaterial's surface.

Download Full-text

Optimizing electron density of nickel sulfide electrocatalysts through sulfur vacancy engineering for alkaline hydrogen evolution

Journal of Materials Chemistry A ◽

10.1039/d0ta05594h ◽

2020 ◽

Vol 8 (35) ◽

pp. 18207-18214

Author(s):

Dongbo Jia ◽

Lili Han ◽

Ying Li ◽

Wenjun He ◽

Caichi Liu ◽

...

Keyword(s):

Hydrogen Evolution ◽

Electron Density ◽

Rational Design ◽

Nickel Sulfide ◽

Catalytic Performance ◽

Sulfide Catalysts ◽

Sulfur Vacancy

A novel, rational design for porous S-vacancy nickel sulfide catalysts with remarkable catalytic performance for alkaline HER.

Download Full-text

Chronic Itch: Research on Mechanisms Leads to Novel Therapies

Internal Medicine News ◽

10.1016/s1097-8690(06)72763-9 ◽

2006 ◽

Vol 39 (3) ◽

pp. 15

Author(s):

BETSY BATES

Keyword(s):

Novel Therapies ◽

Chronic Itch

Download Full-text

Rational design & continuous evolution of minimalist proteins that target the E-box DNA site

10.1021/scimeetings.0c07226 ◽

2020 ◽

Author(s):

Jumi Shin

Keyword(s):

Rational Design ◽

Continuous Evolution ◽

E Box

Download Full-text

Rational design of annotine analogues with increased inhibitory activity towards acetylcholinesterase

Planta Medica ◽

10.1055/s-0036-1596773 ◽

2016 ◽

Vol 81 (S 01) ◽

pp. S1-S381

Author(s):

ES Halldorsdottir ◽

S Oddsson ◽

AM Einarsdottir ◽

B Eiriksdottir ◽

NM Kowal ◽

...

Keyword(s):

Inhibitory Activity ◽

Rational Design

Download Full-text

Anticoagulant Activity of Hirulog™, a Direct Thrombin Inhibitor, in Humans

Thrombosis and Haemostasis ◽

10.1055/s-0038-1651573 ◽

1993 ◽

Vol 69 (02) ◽

pp. 157-163 ◽

Cited By ~ 137

Author(s):

Irving Fox ◽

Adrian Dawson ◽

Peter Loynds ◽

Jane Eisner ◽

Kathleen Findlen ◽

...

Keyword(s):

Rational Design ◽

Therapeutic Potential ◽

Anticoagulant Activity ◽

Subcutaneous Administration ◽

Direct Thrombin Inhibitor ◽

Controlled Study ◽

Thrombin Inhibitor ◽

Thrombin Time ◽

Thrombotic Disease ◽

Dose Dependent

SummaryHirulog™ (BG8967) is a direct thrombin inhibitor built by rational design using the protein hirudin as a model (Maraganore et al. [1990]; Biochemistry 29: 7095–101). In order to evaluate the therapeutic potential for hirulog in the management of thrombotic disease, the tolerability and anticoagulant activity of the agent were examined in a study of human volunteers.In a randomized, placebo-controlled study (n = 54), the intravenous infusion of hirulog over 15 min showed a rapid, dose-dependent prolongation of activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT). There was a corresponding dose-dependent increase in plasma hirulog levels. The peptide was rapidly cleared with a half-life of 36 min and a total body clearance rate for the peptide of 0.43 1 kg−1 h−1. Similar activity was observed following subcutaneous injection but with sustained pharmacodynamic and pharmacokinetic behavior. There was a significant correlation between pharmacokinetic and pharmacodynamic variables for both intravenous (r = 0.8, p <0.001) and subcutaneous administration (r = 0.7, p = 0.002).To evaluate the possible interactions of aspirin on the tolerability and anticoagulant activity of intravenous hirulog, a cross-over design was employed in eight subjects. Aspirin administration did not modify the peptide’s activity. At the administered dose of 0.6 mg kg−1 h−1 for 2 h, hirulog infusion prolonged APTT from 230 to 260% baseline. The infusion of hirulog in subjects who had received aspirin was not associated with any significant changes in the template bleeding time.The final phase of the study examined the activity and tolerability of hirulog in ten subjects during prolonged intravenous infusions for up to 24 h. The peptide (0.3 mg kg−1 h−1) exhibited sustained anticoagulant activity with no evidence for a cumulative effect. During hirulog infusion, APTT was prolonged from 210 to 250% baseline.In all phases of the study, hirulog administration was generally well-tolerated.Our observations show that hirulog is an active antithrombin agent with excellent tolerability in humans. As a direct thrombin inhibitor, hirulog provides a novel approach for the management of thrombotic disease.

Download Full-text